Serum bone resorption markers and 25-hydroxyvitamin D level in women of the Trans-Baikal region of the Russian and Buryat nationalities-Reference-Cited by-同舟云学术

Serum bone resorption markers and 25-hydroxyvitamin D level in women of the Trans-Baikal region of the Russian and Buryat nationalities

Published:2022-12-27 Issue:6 Volume:42 Page:100-107
ISSN:2410-2520
Container-title:Сибирский научный медицинский журнал
language:
Short-container-title:Sibirskij nauchnyj medicinskij zhurnal

Author:

Verkhoturova S. V.¹,Gorbunov V. V.²^ORCID,Tsarenok S. Yu.²^ORCID,Aksenova T. A.²^ORCID,Iljamakova N. A.³

Affiliation:

1. Chita State Medical Academy of Minzdrav of Russia; Clinical Hospital “RZD-Meditsine” of Chita

2. Chita State Medical Academy of Minzdrav of Russia

3. Clinical Hospital “RZD-Meditsine” of Chita

Publisher

Institute of Cytology and Genetics, SB RAS

Reference22 articles.

1. Clinical guidelines. Osteoporosis. 2021. Available at: https://www.endocrincentr.ru/sites/default/files/ specialists/science/clinic-recomendations/osteoporoz. pdf [In Russian].

2. Kanis J.A., Norton N., Harvey N.C., Jacobson T., Johansson H., Lorentzon M., McCloskey E.V., Willers C., Borgström F. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arc. Osteoporosis 2021;16(1):82. doi:10.1007/s11657-020-00871-9

3. Dobrovolskaya O.V., Toportsova N.V., Lesnyak O.M. Economic aspects of complicated osteoporosis: the cost of treatment in the first year after fracture. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(3):29–34. [In Russian]. doi: 10.14412/1996-7012-2016-3-29-34

4. Dzyuba G.G., Stasenko I.N., Kendys T.N., Irbagimova N.A. Assessment of the quality of life in patients with fractures – markers of osteoporosis (observational study). Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2020;23(1):104. [In Russian].

5. Mawatari T., Ikemura S., Matsui G., Iguchi T., Mitsuyasu H., Kawahara S., Maehara M., Muraoka R., Iwamoto Y., Nakashima Y. Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial. Bone Rep. 2020;12:100275. doi: 10.1016/j.bonr.2020.100275